These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 17355112)

  • 21. Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
    Sakamoto H; Kitano M; Suetomi Y; Takeyama Y; Ohyanagi H; Nakai T; Yasuda C; Kudo M
    J Gastroenterol; 2006 Jan; 41(1):70-6. PubMed ID: 16501860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
    Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
    Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
    Kindler HL; Aklilu M; Nattam S; Vokes EE
    Am J Clin Oncol; 2008 Dec; 31(6):553-6. PubMed ID: 19060586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
    Mahadevan D; Chalasani P; Rensvold D; Kurtin S; Pretzinger C; Jolivet J; Ramanathan RK; Von Hoff DD; Weiss GJ
    Am J Clin Oncol; 2013 Jun; 36(3):239-43. PubMed ID: 22441342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
    Brade A; Brierley J; Oza A; Gallinger S; Cummings B; Maclean M; Pond GR; Hedley D; Wong S; Townsley C; Brezden-Masley C; Moore M
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1027-36. PubMed ID: 17197132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of gemcitabine and tamoxifen in advanced pancreatic cancer.
    Tomao S; Romiti A; Massidda B; Ionta MT; Farris A; Zullo A; Brescia A; Santuari L; Frati L
    Anticancer Res; 2002; 22(4):2361-4. PubMed ID: 12174927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
    Cho IR; Kang H; Jo JH; Lee HS; Chung MJ; Park JY; Park SW; Song SY; Chung JB; An C; Park MS; Jung SY; Bang S
    Semin Oncol; 2017 Dec; 44(6):420-427. PubMed ID: 29935903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
    Abratt RP; Hacking DJ; Goedhals L; Bezwoda WR
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-18-S8-23. PubMed ID: 9207311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
    El-Hadaad HA; Wahba HA
    J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma.
    Brembeck FH; Schoppmeyer K; Leupold U; Gornistu C; Keim V; Mössner J; Riecken EO; Rosewicz S
    Cancer; 1998 Dec; 83(11):2317-23. PubMed ID: 9840531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
    Ng EW; Sandler AB; Robinson L; Einhorn LH
    Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine as palliative treatment in patients with unresectable pancreatic cancer previously treated with placement of a covered metal stent. A randomized controlled trial.
    Xinopoulos D; Dimitroulopoulos D; Karanikas I; Fotopoulou A; Oikonomou N; Korkolis D; Kouroumalis E; Antsaklis G; Vassilopoulos P; Paraskevas E
    J BUON; 2008; 13(3):341-7. PubMed ID: 18979547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
    Possinger K; Kaufmann M; Coleman R; Stuart NS; Helsing M; Ohnmacht U; Arning M
    Anticancer Drugs; 1999 Feb; 10(2):155-62. PubMed ID: 10211545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Ikeda M; Okada S; Tokuuye K; Ueno H; Okusaka T
    Br J Cancer; 2002 May; 86(10):1551-4. PubMed ID: 12085203
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
    Girard N; Mornex F; Bossard N; Ychou M; Chauffert B; Wautot V
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1426-32. PubMed ID: 20056351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
    Kindler HL; Friberg G; Singh DA; Locker G; Nattam S; Kozloff M; Taber DA; Karrison T; Dachman A; Stadler WM; Vokes EE
    J Clin Oncol; 2005 Nov; 23(31):8033-40. PubMed ID: 16258101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
    Zatloukal P; Kanitz E; Magyar P; Jassem J; Krzakowski M; Pawlicki M; Petruzelka L; Chovan L; Pesek M; Janko C; Krejcy K
    Lung Cancer; 1998 Dec; 22(3):243-50. PubMed ID: 10048477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
    Vogl TJ; Schwarz W; Eichler K; Hochmuth K; Hammerstingl R; Jacob U; Scheller A; Zangos S; Heller M
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):745-55. PubMed ID: 16858591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
    Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
    Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.